CTLA-4 as a Double-Edged Sword in Colorectal Cancer: Molecular Insights into Immune Checkpoint Suppression and Therapeutic Targeting
Gut and Liver · 2026
DOI: 10.5009/gnl260025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gut and Liver, 2026. Verfasst von Husin Thamrin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Colorectal Neoplasms, Immune Checkpoint Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a major global health burden and ranks third among the most commonly diagnosed malignancies and the second leading cause of cancer-related mortality worldwide. Its development arises through successive molecular and cellular alterations driven by cumulative genetic mutations, environmental exposure, and immune dysregulation. Among immune regulators, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) plays dual roles in CRC progression. On one hand, CTLA-4 preserves immune homeostasis by restraining excessive T-cell activation through competitive binding with CD80/CD86. This regulatory function is mediated by attenuated T-cell receptor signaling, dominance over CD28-mediated co-stimulation, and sustained activity of regulatory T cells to maintain peripheral tolerance. On the other hand, this inhibitory mechanism facilitates tumor immune evasion and contributes to cancer progression by limiting effector T-cell proliferation, reducing cytotoxic activity, and promoting immune exhaustion within the tumor microenvironment. Therapeutically, antibodies such as ipilimumab and tremelimumab leverage these roles by blocking CTLA-4 to restore antitumor immunity. However, the downstream signaling cascades following CTLA-4 activation and the detailed molecular basis of tremelimumab-mediated modulation are not yet fully understood. More detailed understanding of these dual-role mechanisms through integrative molecular, cellular, and structural analyses may help refine immune checkpoint blockade strategies and improve therapeutic outcomes in CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
- Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
- Division of Gastroentero-Hepatology, Department of Internal Medicine, Dr. Soetomo Teaching Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
- Helicobacter pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.
ORCID-Profile: Husin Thamrin, Gondo Mastutik, Muhammad Miftahussurur
Zitieren
APA
Thamrin, H., Mastutik, G., & Miftahussurur, M. (2026). CTLA-4 as a Double-Edged Sword in Colorectal Cancer: Molecular Insights into Immune Checkpoint Suppression and Therapeutic Targeting. Gut and Liver. https://doi.org/10.5009/gnl260025
Vancouver
Thamrin H, Mastutik G, Miftahussurur M. CTLA-4 as a Double-Edged Sword in Colorectal Cancer: Molecular Insights into Immune Checkpoint Suppression and Therapeutic Targeting. Gut and Liver. 2026. doi:10.5009/gnl260025
BibTeX
@article{Thamrin2026,
author = {Thamrin, Husin and Mastutik, Gondo and Miftahussurur, Muhammad},
title = {CTLA-4 as a Double-Edged Sword in Colorectal Cancer: Molecular Insights into Immune Checkpoint Suppression and Therapeutic Targeting},
journal = {Gut and Liver},
year = {2026},
doi = {10.5009/gnl260025}
}
EUVIMED